Theranos, the $9 billion biotechnology startup that officially dissolved last year after allegations of fraud, is a warning for investors in life sciences. Namely, a lack of transparency within portfolio companies creates the possibility of another multibillion dollar implosion, according to researchers from the Meta-Research Innovation Center at Stanford.